Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Increased ALK

Increased ALK ORIGINAL ARTICLE Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc,*†‡ Lara Pijuan, MD, PhD,*‡ Luz Martínez-Avile ´s, MSc,*‡ Ana B. Galva ´ n, MSc,* Israel Can ˜ adas, MSc,‡ Ana Rovira, PhD,‡§ Montserrat Zanui, MD,§ Alejandro Martínez, MD,‡§ Raquel Longaro ´ n,* Francisco Sole, PhD,*‡ Sergio Serrano, MD, PhD,*‡ Beatriz Bellosillo, PhD,*‡ Murry W. Wynes, PhD,¶ Joan Albanell, MD, PhD,‡§ Fred R. Hirsch, MD, PhD,¶ and Edurne Arriola, MD, PhD‡§ amplification in the response to ALK inhibitors alone or combined Introduction: Translocation of the anaplastic lymphoma kinase with EGFR inhibitors in NSCLC merits further studies. (ALK) gene is involved in the tumorigenesis of a subset of non-small Key Words: ALK, Non-small cell lung cancer, Amplification, cell lung carcinomas (NSCLCs) and identifies patients sensitive to Translocation, Polysomy. ALK inhibitors. ALK copy number changes and amplification, which plays an oncogenic role in tumors such as neuroblastoma, are poorly (J Thorac Oncol. 2011;6: 21–27) characterized in NSCLC. We aimed to study the prevalence of ALK copy number changes and their correlation to ALK protein expres- sion, epidermal growth factor receptor (EGFR) status, and clinico- ung cancer is the leading cause in the cancer-related http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Increased ALK

Arriola, Edurne
Journal of Thoracic Oncology , Volume 6 (1) – Jan 1, 2011
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/increased-alk-oZ5ws13uw8

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181fb7cd6
pmid
21107285
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc,*†‡ Lara Pijuan, MD, PhD,*‡ Luz Martínez-Avile ´s, MSc,*‡ Ana B. Galva ´ n, MSc,* Israel Can ˜ adas, MSc,‡ Ana Rovira, PhD,‡§ Montserrat Zanui, MD,§ Alejandro Martínez, MD,‡§ Raquel Longaro ´ n,* Francisco Sole, PhD,*‡ Sergio Serrano, MD, PhD,*‡ Beatriz Bellosillo, PhD,*‡ Murry W. Wynes, PhD,¶ Joan Albanell, MD, PhD,‡§ Fred R. Hirsch, MD, PhD,¶ and Edurne Arriola, MD, PhD‡§ amplification in the response to ALK inhibitors alone or combined Introduction: Translocation of the anaplastic lymphoma kinase with EGFR inhibitors in NSCLC merits further studies. (ALK) gene is involved in the tumorigenesis of a subset of non-small Key Words: ALK, Non-small cell lung cancer, Amplification, cell lung carcinomas (NSCLCs) and identifies patients sensitive to Translocation, Polysomy. ALK inhibitors. ALK copy number changes and amplification, which plays an oncogenic role in tumors such as neuroblastoma, are poorly (J Thorac Oncol. 2011;6: 21–27) characterized in NSCLC. We aimed to study the prevalence of ALK copy number changes and their correlation to ALK protein expres- sion, epidermal growth factor receptor (EGFR) status, and clinico- ung cancer is the leading cause in the cancer-related

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2011

References

  • Cancer statistics, 2008
    Jemal
  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    Paez
  • Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    Uramoto
  • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    Soda
  • Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
    Morris
  • ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
    Gascoyne
  • Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
    Griffin
  • Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
    Ma
  • Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK)
    Settleman
  • Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
    Rodig
  • Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Shaw
  • EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
    Inamura
  • EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    Inamura
  • EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues
    Martelli